APP and early-onset autosomal dominant Alzheimer disease: In a genetic form of Alzheimer’s disease, the targeting of 37/67 kDa LR by NSC48478 inhibits the aberrant endocytosis of APP and improves homeostasis of the endocytic network and trafficking [49].